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Regulation of Fasting Fuel Metabolism by Toll-Like
Receptor 4
Shanshan Pang, Haiqing Tang, Shu Zhuo, Ying Qin Zang, and Yingying Le
OBJECTIVE—Toll-like receptor 4 (TLR4) has been reported to
induce insulin resistance through inﬂammation in high-fat–fed
mice. However, the physiological role of TLR4 in metabolism is
unknown. Here, we investigated the involvement of TLR4 in
fasting metabolism.
RESEARCH DESIGN AND METHODS—Wild-type and TLR4
deﬁcient (TLR4
/) mice were either fed or fasted for 24 h.
Glucose and lipid levels in circulation and tissues were mea-
sured. Glucose and lipid metabolism in tissues, as well as the
expression of related enzymes, was examined.
RESULTS—Mice lacking TLR4 displayed aggravated fasting
hypoglycemia, along with normal hepatic gluconeogenesis, but
reversed activity of pyruvate dehydrogenase complex (PDC) in
skeletal muscle, which might account for the fasting hypoglyce-
mia. TLR4
/ mice also exhibited higher lipid levels in circula-
tion and skeletal muscle after fasting and reversed expression of
lipogenic enzymes in skeletal muscle but not liver and adipose
tissue. Adipose tissue lipolysis is normal and muscle fatty acid
oxidation is increased in TLR4
/ mice after fasting. Inhibition
of fatty acid synthesis in TLR4
/ mice abolished hyperlipid-
emia, hypoglycemia, and PDC activity increase, suggesting that
TLR4-dependent inhibition of muscle lipogenesis may contribute
to glucose and lipid homeostasis during fasting. Further studies
showed that TLR4 deﬁciency had no effect on insulin signaling
and muscle proinﬂammatory cytokine production in response to
fasting.
CONCLUSIONS—These data suggest that TLR4 plays a critical
role in glucose and lipid metabolism independent of insulin
during fasting and identify a novel physiological role for TLR4 in
fuel homeostasis. Diabetes 59:3041–3048, 2010
M
ammals have evolved complex metabolic sys-
tems to adapt to food deprivation. Under
fasting condition, the triglycerides (TGs)
stored in white adipose tissue (WAT) are
hydrolyzed to release free fatty acids (FFAs), which be-
come the primary fuel for liver and muscle through fatty
acid oxidation (FAO) (1). Meanwhile, de novo fatty acid
synthesis is strongly inhibited (2). During prolonged fast-
ing, blood glucose levels are maintained within a narrow
range to prevent life-threatening hypoglycemia, mainly
through activation of hepatic gluconeogenesis. Glucose
can also be spared by skeletal muscle through inhibition of
pyruvate dehydrogenase complex (PDC) activity (3,4).
PDC catalyzes the formation of acetyl-CoA from pyruvate,
leading to irreversible net loss of carbohydrate. These
metabolic adaptations to fasting are tightly regulated by
several hormones, such as glucagon, glucocorticoids, epi-
nephrine, and, recently reported, ﬁbroblast growth factor
21 (5,6).
TLR4 is one of the mammalian pattern recognition
receptors, recognizing pathogen-associated molecules and
playing pivotal roles in innate immune response (7).
Recently, saturated fatty acids have been reported to
enhance the secretion of proinﬂammatory chemokines
and cytokines through TLR4 activation (8–10). The activa-
tion of TLR4 by saturated fatty acids is believed to link
obesity, inﬂammation, and insulin resistance (11–15). Mice
with either deletion or mutation of TLR4 resist fatty acids-
or high-fat diet–induced insulin resistance (11–13,15).
Further, hematopoietic cell-speciﬁc deletion of TLR4 ame-
liorates heptic and adipose tissue insulin resistance in
high-fat–fed mice (14). Given that these studies clearly
demonstrate pathophysiological roles for TLR4 in meta-
bolic disorders, such as obesity and insulin resistance,
we propose that TLR4 may also play important roles
in metabolic regulation under physiological conditions. In
this study, we investigate the involvement of TLR4 in
fasting metabolism and provide in vivo evidence that TLR4
plays an essential role in the physiological regulation of
fuel homeostasis.
RESEARCH DESIGN AND METHODS
Animal experiments. TLR4
/ mice with a C57BL/6 background (16) were
kindly provided by Prof. Vincent Deubel and Prof. Baoxue Ge (Institute
Pasteur of Shanghai, Chinese Academy of Sciences). Wild-type (C57BL/6)
mice were purchased from the Shanghai Laboratory Animal Co. Mice were
housed under a 12-h dark/light cycle with free access to standard chow and
water. For experiments, 6- to 8-week-old male wild-type and TLR4
/ mice
were housed individually and fasted at 9:00 A.M. Twenty-four hours later, mice
were killed and serum, liver, epididymal fat, and gastrocenimus muscle were
collected and snap-frozen in liquid nitrogen for further analysis. All experimental
procedures and protocols were approved by the Institutional Animal Care and
Use Committee of the Institute for Nutritional Sciences, Chinese Academy of
Sciences.
For C75 (Sigma) treatment, mice received intraperitoneal injection of 20
mg/kg C75 dissolved in 200 l RPMI-1640 right before fasting; control mice
were injected with 200 l RPMI accordingly. For the insulin tolerance test,
mice were fasted for 24 h and blood glucose was assessed before insulin
(novolin) injection (0.25 units/kg i.p.) and at 15, 30, 45, and 60 min after
injection. For the pyruvate tolerance test, mice were fasted for 24 h and blood
glucose were assessed before pyruvate injection (2g/kg i.p.) and at 20, 40, 60,
and 80 min after injection.
Assessment of energy expenditure and respiratory quotient. O2 and CO2
consumption were determined in the comprehensive laboratory animal mon-
itoring system (CLAMS; Columbus Instruments) according to the manufactur-
er’s instructions. Animals were acclimated to the system for 18–24 h with free
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diabetes.diabetesjournals.org DIABETES, VOL. 59, DECEMBER 2010 3041access to food and water, and the measurements were conducted for 24 h
from 9:00 A.M. without food supply.
Metabolic parameters analysis. Total fat mass was measured by nuclear
magnetic resonance with a Minispec Mq7.5 Analyzer (Bruker, Germany).
Blood glucose was determined using a glumeter (Freestyle). Serum levels of
TG and FFA were determined by an enzymatic triglyceride assay kit (Apply-
gen, Beijing) and a LabAssay non-esteriﬁed fatty acids (NEFA) kit (Wako),
respectively. Serum levels of lactate, alanine and pyruvate were determined by
enzymatic kits (Biovision). Serum insulin levels were determined by an ELISA
kit (Millipore). Tissue TG content was measured as previously described (17).
Brieﬂy, frozen liver and gastrocenimus muscle were weighted, homogenized
in isopropanol, incubated at 4°C for 1 h, and centrifuged. The supernatants
were collected to measure TG concentrations by the enzymatic kit.
Lipolysis assay. Lipolysis studies were performed in explants from freshly
isolated edipidymal fat as previously described (18). Brieﬂy, fat explants from
mice fasted for 24 h were incubated in Krebs-Ringer buffer (12 mmol/l HEPES,
121 mmol/l NaCl, 4.9 mmol/l KCl, 1.2 mmol/l MgSO4, and 0.33 mmol/l CaCl2)
with 3.5% fatty acid–free BSA and 0.1% glucose. Glycerol (Applygen, Beijing)
and NEFA (Wako) contents were measured after one-hour incubation.
Muscle fatty acid oxidation. Fatty acid oxidation rate was determined
in muscle homogenates as previously described (19) with modiﬁcations.
Brieﬂy, muscle homogenates were incubated with reaction mixture, in which
[
3H]oleate was used as substrate. After incubation, reaction medium was
added with 2.5 ml methanol:chloroform (1:2) and 1 ml 2 mol/l KCl/2 mol/l HCl
to separate the aqueous phase, which contains
3H2O and was taken for
scintillation counting.
PDC activity assay. Actual PDC activity in gastrocenimus muscle was
measured by an assay coupling with arylamine N-acetyltransferase as previ-
ously described (20). One unit of PDC activity corresponds to the acetylation
of 1 mol p-(paminophenylazo)benzene sulfonic acid/min at 30°C.
RNA extraction and real-time PCR. Total RNA was extracted from tissues
using TRIzol reagent (Invitrogen, Carlsbad, CA) and treated with RNase-Free
DNase. First-strand cDNA was synthesized with M-MLV reverse transcriptase
and oligo (dT) primers. Real-time quantitative PCR was performed on an ABI
Prism 7900 sequence detection system (Applied Biosystems), using SYBR
Green PCR Master Mix (Applied Biosystems). The results were normalized
against 36B4 gene expression. The primer sequences are available upon
request.
Western blot analysis. Tissue was homogenized in radioimmunoprecipita-
tion assay lysis buffer and centrifuged to remove the debris. Proteins were
separated by SDS-PAGE, transferred to polyvinylidene ﬂuoride membrane,
and blocked in 5% nonfat milk at room temperature for 1 h.The membrane was
incubated overnight at 4°C with the following primary antibodies: mouse
anti-fatty acid synthase (FAS) (BD Transduction Laboratories) and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) (KANGCHEN, China), rabbit
anti–ATP citrate lyase (ACL), IB, phosphorylated levels of insulin receptor,
phosphorylated levels of Akt, and phosphorylated levels of glycogen synthase
kinase (GSK)3 (Cell Signaling). After washing, the blots were incubated with
horseradish peroxidase–conjugated anti-mouse or rabbit immunoglobulin G
secondary antibody for1ha troom temperature and then developed with
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientiﬁc).
Statistical analysis. Data are presented as means  SEM. Statistical
signiﬁcance was determined using two-tailed unpaired Student’s t test. A value
of P  0.05 was considered signiﬁcant.
RESULTS
TLR4
/ mice exhibit aggravated fasting hypoglyce-
mia. We ﬁrst examined the involvement of TLR4 in
glucose metabolism in response to fasting. After fasted for
24 h, TLR4
/ mice exhibited signiﬁcantly lower blood
glucose levels than wild-type controls (wild type: 82  2.42
mg/dl, TLR4
/: 65.11  2.48 mg/dl; P  0.001), whereas
no difference was observed in the fed state (Fig. 1A),
suggesting an essential role for TLR4 in maintaining fast-
ing blood glucose levels.
To explore the mechanisms underlying the severe fast-
ing hypoglycemia, we ﬁrst focused on hepatic glucose
production. We examined the expression levels of key
enzymes governing FAO and gluconeogenesis in liver. No
differences in the mRNA levels of medium-chain acyl-CoA
dehydrogenase (MCAD)o rPPARa were observed be-
tween wild-type and TLR4
/ mice (Fig. 1B). Surprisingly,
TLR4 deﬁciency increased the mRNA levels of carnitine
palmitoyltransferase 1 (CPT1) in the liver (Fig. 1B) and the
-hydroxybytyrate levels in the serum (Fig. 1C). mRNA
levels of PEPCK in TLR4
/ mice were comparable with
those in wild-type controls, while G6Pase only showed a
tendency to decrease in TLR4
/ mice (P  0.071) (Fig.
1D). To further compare the abilities of gluconeogenesis
between mice, we performed a pyruvate tolerance test. As
expected, wild-type and TLR4
/ mice showed similar
glycemic responses to pyruvate after fasting (Fig. 1E),
indicating comparable capacities of gluconeogenesis.
Also, no differences in the serum levels of gluconeogenic
substrates, including lactate, alanine, and pyruvate, were
observed between wild-type and TLR4
/ mice in the
fasted state (Fig. 1F). These data suggest that the fasting
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FIG. 1. Severe fasting hypoglycemia and normal hepatic gluconeogenesis in TLR4
/ mice. Male wild-type (WT) and TLR4
/ mice were either fed
or fasted for 24 h. A: Blood glucose levels; n  9–10. B: mRNA levels of CPT1, MCAD, and PPAR in liver. C: Circulating levels of
-hydroxybytyrate. D: mRNA levels of PEPCK and G6Pase (G6P) in liver. E: Pyruvate tolerance test after 24 h of fasting; n  8–9. F: Serum levels
of gluconeogenic substrates in the fasted state. All data shown are means  SEM; n  4–5 unless otherwise indicated. *P < 0.05, ***P < 0.001
vs. wild-type mice.
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/ mice does not result from
impaired hepatic gluconeogenesis.
TLR4 deﬁciency reverses PDC activity and glycolytic
enzymes expression in skeletal muscle during fast-
ing. During fasting, glucose could also be spared by
blocking the irreversible net loss of glucose in skeletal
muscle through PDC inhibition (3,4). PDC consists of
three enzymes: pyruvate dehydrogenase (PDHA1), dihy-
drolipoamide acetyltransferase (DLAT), and dihydrolipo-
amide dehydrogenase (DLD). We found that fasting
signiﬁcantly inhibited PDC activity in skeletal muscle of
wild-type mice. Notably, the inhibition was largely re-
versed by TLR4 deletion (Fig. 2A). In addition, fasting
inhibited the mRNA expression of all three enzymes of
PDC in wild-type mice, whereas it only inhibited the
expression of DLAT in TLR4
/ mice (Fig. 2B). These
results suggest that unsuppressed PDC activity in skeletal
muscle contributes at least partly to the severe fasting
hypoglycemia in TLR4
/ mice. We also found that TLR4
deﬁciency reversed the mRNA levels of hexokinase 2
(HK2) and muscle phosphofructokinase (PFKM), two rate-
limiting enzymes of glycolysis, in skeletal muscle during
fasting (Fig. 2C), suggesting that glycolysis may also be
reversed by TLR4 deﬁciency.
TLR4 deﬁciency increases lipid levels in circulation
and skeletal muscle in response to fasting. We next
examined the involvement of TLR4 in lipid metabolism.
Compared with wild-type mice, TLR4
/ mice exhibited
higher levels of TG and FFA in circulation after fasting and
similar serum levels of TG and FFA in the fed state (Fig. 3A
and 3B). In liver, TG levels were increased in response to
fasting in both wild-type and TLR4
/ mice, with a ten-
dency to be higher in TLR4
/ mice (Fig. 3C). In skeletal
muscle, a 2.5-fold increase in TG content was observed
in TLR4
/ mice in the fasted state only (Fig. 3D). These
ﬁndings indicate that TLR4 deﬁciency elevates lipid levels in
skeletal muscle and circulation in response to starvation.
TLR4
/ mice exhibit normal adipose tissue lipolysis
and increased muscle fatty acid oxidation during
fasting. The lipid abnormalities in TLR4
/ mice might
result from increased TG mobilization in WAT, decreased
FAO, and/or increased de novo lipogenesis in key meta-
bolic tissues. We found that fasting signiﬁcantly reduced
total fat mass in both wild-type and TLR4
/ mice but with
less loss in TLR4
/ mice (Fig. 4A). Consistently, TLR4
/
mice exhibited less epididymal fat loss during fasting (Fig.
4B). We also performed lipolysis assay in epididymal fat
explants from fasted mice. Wild-type and TLR4
/ mice
exhibited similar glycerol release rates (Fig. 4C), indicat-
ing comparable lipolysis. Interestingly, TLR4
/ mice
showed lower NEFA release than wild-type mice, resulting
in a signiﬁcant reduction in NEFA-to-glycerol ratio (Fig.
4C), indicating increased fatty acid reesteriﬁcation. These
data suggest that the higher lipid levels in TLR4
/ mice
do not result from increased fat mobilization.
As to muscle FAO, TLR4 deﬁciency increased the mRNA
levels of CPT1 and MCAD after fasting and had no effect
on the expression of PPARa (Fig. 4D). The mRNA levels of
acetyl-CoA carboxylase 2 (ACC2), which inhibits CPT1
through its product mitochondrial malonyl-CoA (21), were
similar between two sets of mice (Fig. 4D), indicating that
ACC2-related regulation may not be involved in the aug-
mentation of CPT1 in TLR4
/ mice. More importantly,
TLR4
/ mice exhibited increased muscle FAO rates
compared with wild-type mice after fasting (Fig. 4E).
These observations suggest that FAO does not contribute
to the higher lipid levels in TLR4
/ mice.
TLR4 is required for inhibition of lipogenic genes in
skeletal muscle during fasting. We then examined the
expression of enzymes regulating de novo fatty acid
synthesis, including ACC1, ACL, and FAS. Fasting de-
creased the expression of these enzymes in liver, WAT,
and muscle (Fig. 5A–C). Surprisingly, TLR4 deﬁciency
resulted in a complete reversion of the mRNA levels of
ACC1 and ACL and a partial reversion of FAS in muscle
but not liver or WAT (Fig. 5A-5C). TLR4 deﬁciency also
fully reversed the protein levels of ACL and FAS in muscle
but not liver (Fig. 5D-5E). In addition, the mRNA expres-
sion of elongation of very long–chain fatty acids, family
member 6 (Elovl6) and stearoyl-CoA desaturase 1 (SCD1),
two other important enzymes regulating fatty acid synthe-
sis, showed a pattern simiar to that of FAS in skeletal muscle
(Fig. 5C). Consistently, the mRNA levels of glycerol-3-
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FIG. 3. Increased lipid levels in serum and skeletal muscle of TLR4
/
mice in response to fasting. Male wild-type (WT) and TLR4
/ mice
either fed or fasted for 24 h were examined for serum levels of TG (A)
and FFA (B) and TG levels in liver (C) and skeletal muscle (D). All
data shown are means  SEM; n  4–7. *P < 0.05, **P < 0.01, ***P <
0.001 vs. wild-type mice.
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acyltransferase 1 (DGAT1), two enzymes controlling TG
synthesis, were also higher in skeletal muscle of TLR4
/
mice (Fig. 5C). The mRNA levels of SREBP1c and PPAR,
two transcription factors controlling lipogenesis (22,23),
were all decreased in the skeletal muscle of wild-type and
TLR4
/ mice after fasting, but TLR4
/ mice had a
higher levels of PPAR (Fig. 5F), suggesting that PPAR	
might be involved in TLR4-dependent inhibition of lipo-
genic genes in skeletal muscle. Collectively, these data
suggest that TLR4 is required for the inhibition of lipogenic
genes in skeletal muscle during fasting and provide a
possible explanation for the relatively higher TG levels in
skeletal muscle but not liver or WAT of TLR4
/ mice.
To further test the contribution of lipid synthesis to the
serum lipids in TLR4
/ mice, we treated mice with C75,
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synthesis. After fasting, vehicle-treated TLR4
/ mice
showed elevated serum levels of TG and FFA (Fig. 5G and
5H)—similar to untreated mice. Notably, C75 treatment
fully abolished these elevations (Fig. 5G and 5H). Together
with our observation that FAS expression was only re-
versed in muscle, but not liver and WAT, these data
indicate that TLR4 may be involved in fasting serum lipids
regulation by governing muscle fatty acid synthesis.
TLR4 maintains homeostasis between glucose and
lipid fuel during fasting. Because de novo fatty acid
synthesis uses acetyl-CoA oxidized from pyruvate as sub-
strate, we asked whether TLR4 controls PDC activity and
blood glucose levels through fatty acid synthesis regula-
tion. As expected, we found that C75 treatment abolished
the increase in muscle PDC activity and the severe fasting
hypoglycemia resulting from TLR4 deﬁciency (Fig. 6A and
6B). These ﬁndings indicate that excess acetyl-CoA from
increased muscle pyruvate oxidative decarboxylation in
TLR4
/ mice may enter lipogenesis instead of TCA cycle.
Thus, to better understand the effect of TLR4 deﬁciency on
systemic fuel utilization, energy expenditure and respira-
tory quotient (RQ) were determined. During fasting, total
energy expenditure was comparable in TLR4
/ mice and
wild-type mice (Fig. 6C). The RQ of wild-type and TLR4
/
mice exhibited a similar pattern, with a rapid decrease
after fasting followed by a steady level, indicating the shift
of fuel utilization from carbohydrates to fat. However, the
RQ of TLR4
/ mice decreased to a lower level than that
of wild-type mice (Fig. 6D), indicating that more fat was
used as energy. The lower RQ level in TLR4
/ mice is
consistent with their increased FAO rates and supports
that the products of pyruvate oxidative decarboxylation
may be used for lipogenesis. Collectively, these data
suggest an important role for TLR4 in maintaining the
homeostasis between glucose and lipid fuel during fasting.
Insulin signaling and local inﬂammation are not in-
volved in TLR4-dependent regulation of fasting me-
tabolism. TLR4 has been reported to modulate insulin
action by enhancing proinﬂammatory cytokine expression
(13). However, TLR4 deﬁciency had no effect on circulat-
ing insulin levels and insulin sensitivity during fasting (Fig.
7A and B). In addition, phosphorylated levels of insulin
receptor, Akt, and GSK3, key molecules of insulin signal-
ing, were comparable in skeletal muscle between wild-
type and TLR4
/ mice upon insulin stimulation in the
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levels (B). C and D: Measurements of oxygen consumption (C) and RQ
(D) during fasting were carried out in the metabolic cage during
fasting. All data shown are means  SEM; n  4–6. *P < 0.05, **P <
0.01, ***P < 0.001 vs. wild-type (WT) mice.
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the mRNA levels of tumor necrosis factor  (TNF)o r
interleukin-6 (IL-6) in skeletal muscle between wild-type
and TLR4
/ mice (Fig. 7D). Nuclear factor-B is the key
molecule mediating TLR4 activation–induced proinﬂam-
matory cytokine expression. Consistently, TLR4
/ mice
had protein levels of IB comparable with those of
wild-type controls in skeletal muscle after fasting (Fig.
7E). These results suggest that TLR4 regulates fasting
metabolic adaptations in skeletal muscle independent of
insulin and local inﬂammation.
DISCUSSION
The goal of this study was to investigate the physiological
role of TLR4 in metabolism. We found that TLR4 played an
important role in glucose and lipid metabolism in response
to starvation through regulation of critical metabolic path-
ways in skeletal muscle, including pyruvate oxidative
decarboxylation and de novo lipogenesis.
TLR4
/ mice exhibited exacerbated fasting hypoglyce-
mia along with unimpaired hepatic gluconeogenesis. Strik-
ingly, we observed that starvation inhibited the PDC
activity in skeletal muscle of wild-type mice and that this
inhibition was markedly reversed in TLR4-deﬁcient mice.
Inhibition of PDC activity is essential for glucose preser-
vation because acetyl-CoA could not be reconverted to
pyruvate. The decline in PDC activity permits cycling of
carbon between glycolysis and gluconeogenesis and thus
maintains blood glucose even if glycolysis is active (3).
Besides, Jeoung et al. (25) have reported that partially
reversed fasting PDC activity by pyruvate hydrogenase
kinase 4 deletion, a critical PDC kinase, results in exacer-
bated fasting hypoglycemia in mice. Thus, although other
mechanism(s) may also be involved, our results clearly
suggest an essential role for TLR4 in sparing glucose
during starvation, at least in part, through PDC inhibition
in skeletal muscle. Interestingly, the reversed PDC activity
is accompanied with the reversed mRNA expression of
two of its components, PDHA1 and DLD. Thus, although
the PDC activity is generally controlled by reversible
phosphorylation (26), regulation at the transcriptional
level may also be involved. Intriguingly, the protein levels
of PDHA1 in mitochondrial extracts do not change during
fasting (25); we therefore measured the mRNA levels of
superoxide dismutase 2 (SOD2), a reference mitochon-
drial marker. We found that fasting did not affect the
expression of SOD2 in wild-type mice (data not shown),
indicating that the suppressive effect is speciﬁc to compo-
nents of PDC.
During fasting, PDC inhibition is closely paralleled by a
reduced rate of glycolysis. Intriguingly, the mRNA expres-
sion of glycolytic enzymes, HK2 and PFKM, was also
reversed in TLR4
/ mice, which is indicative of reversed
glycolysis. These results indicate that TLR4 may be in-
volved in inhibiting muscle glucose disposal through co-
ordinate suppression of glycolysis and pyruvate oxidative
decarboxylation during fasting. In addition, we found that,
in murine primary muscle cells, activation of TLR4 by
lipopolysaccharide had no effect on either PDC activity or
expression of HK2 and PFKM (data not shown), indicating
that the regulation of these enzymes by TLR4 during
fasting may not be direct.
TLR4
/ mice also exhibited higher lipid levels in
muscle and circulation in the fasted state. These mice
showed less fat loss but similar adipose lipolysis capacity
compared with wild-type mice, ruling out the contribution
of fat mobilization to serum lipid elevation. In fat lipolysis
assay, we unexpectedly observed a decreased ratio of
NEFA to glycerol in fasted TLR4
/ mice, indicating that
the higher serum lipid may contribute to less fat loss,
possibly through increased fatty acid reesteriﬁcation.
TLR4
/ mice also showed increased expression of FAO
genes and FAO rates in muscle, as well as reduced RQ
levels during fasting, arguing against decreased FAO as a
contributor to lipid abnormalities.
In terms of lipogenesis, FAS inhibitor C75 treatment
abolished the elevations of serum lipids in TLR4 mice.
Although the effect of C75 is not tissue speciﬁc, TLR4
deﬁciency reversed FAS expression in skeletal muscle
only, not liver or WAT, during fasting, indicating that C75
effect on muscle FAS may account for its abolishment on
serum lipid increases. It is therefore likely that reversed
muscle lipogenesis in TLR4
/ mice may contribute to
blood lipid increases during fasting, although other tissue
(like the skeleton) may also be involved. We also found
that TLR4 deletion increased the mRNA levels of CD36 but
had no effect on LPL expression in the skeletal muscle
during fasting (data not shown), arguing against the pos-
sibility that TLR4 deﬁciency increases circulating lipid
levels by inhibiting muscle FFA or TG uptake. Thus, how
dysregulated muscle lipogenesis under a fasting condition
contributes to the lipid disturbance in circulation requires
further investigation.
Liver and WAT are widely considered major lipogenic
tissues. However, muscle tissue may also actively partici-
pate in de novo lipogenesis. Several studies around the
1970s showed that liver and dissectible adipose tissue
usually contribute to no more than 40% of total fatty acid
synthesis rate in rodents. Instead, the rest of carcass,
mainly muscle and skeleton, is the major site of fatty acid
synthesis (27–32). Although there was one study that
suggested that the intermuscular fat in carcass might
contribute to lipogenesis (33), several following studies
using dissected muscle without fat showed that muscle
tissue may be an important lipogenic tissue because of its
large mass (27,34,35). Interestingly, in the fasted state,
liver’s contribution to lipogenesis becomes almost negligi-
ble (31,36), whereas muscle may be one of the predomi-
nant tissues for lipogenesis (36). Recently, several
myotube cell-based studies have also supported an active
capacity of muscle in de novo lipogenesis. The expression
of SREBP1c, a key lipogenic transcription factor, is clearly
detectable in muscle at a level close to the liver (37). Upon
insulin or glucose stimulation, muscle SREBP1c regulates
the transcription of lipogenic enzymes, such as FAS and
ACL (37,38). Glucose also stimulates muscle de novo
lipogenesis, which in turn results in lipid accumulation in
myotubes (38,39). Taken together, these studies support
an active role for muscle in lipogenesis, although its
role(s) under physiological or pathophysiological condi-
tions requires further investigation.
Glucose and lipid are tightly related in metabolism. In
the glucose–fatty acid cycle, FAO suppresses PDC activity
by increasing the ratio of acetyl-CoA to CoA (40). Intrigu-
ingly, TLR4 may control glucose metabolism through
regulation of de novo fatty acid synthesis, because FAS
inhibition abolished the fasting hypoglycemia and muscle
PDC activity increase in TLR4
/ mice. Since de novo
fatty acid synthesis uses acetyl-CoA as substrate, it is
conceivable that de novo fatty acid synthesis regulates
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CoA. These ﬁndings indicate that not only lipid oxidation
but also lipid synthesis may affect muscle glucose
metabolism.
Currently, it is unclear how TLR4 is activated and
regulates these metabolic pathways during fasting. Unlike
its reported role in insulin resistance (13), TLR4-depen-
dent regulation of fasting metabolism is neither insulin nor
inﬂammation dependent. During starvation, the increases
in fatty acids have been reported to modulate muscle PDC
activity (41,42). However, although direct FAO is generally
thought to mediate the acute effect of FFA on PDC activity
(41), it is not responsible for this long-term (starvation)
regulation of muscle PDC (43), indicating the existence of
alternative mechanism(s). Because saturated fatty acids
have been reported as the agonists for TLR4 (8–10), it is
possible that TLR4 activation by FFA regulates muscle
PDC activity during starvation. Hormone signaling, such as
triiodothyronine, is critical for PDC activity modulation
during the fed-to-starved transition (41,44), raising the
possibility that TLR4 regulates fasting metabolism through
cross-talk with other hormone signaling. These interesting
hypotheses require further investigation.
In summary, our ﬁndings identify TLR4 as a physiolog-
ical regulator of fuel metabolism independent of insulin
and identify a novel physiological role for TLR4 in metab-
olism. Muscle lipogenesis may play an important role in
maintaining fasting fuel homeostasis.
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